ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0849

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Creating a Foundation for Linking Patient Reported Outcomes Measures with the International Classification of Functioning, Disability and Health

Hannah Bailey1, Ananya Vasudevan1, Emily Hickey2, Aileen Ledingham3, Mary Slavin1, Lewis Kazis4 and Ronald Tompkins5, 1Boston University School of Public Health, Boston, MA, 2University of Wisconsin, Madison, WI, 3Boston University School of Public Health, Waltham, MA, 4Boston University, Spaulding Hospital and Harvard Medical School, Boston, MA, 5Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2021

Keywords: Comon Data Elements, International Classification of Functioning, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Research Methodology Poster (0846–0854)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a devastating multi-system chronic disease, estimated to affect 1.5 million adults in the United States. The disease is associated with immune, neurological, metabolic, cognitive and sleep impairments compounded principally by Post-Exertional Malaise (PEM) and dysautonomia associated with a pathological level of fatigue. Among people with ME/CFS, 70% cannot work; 25% are home- or bed-bound, and recovery is rare. There are no FDA-approved drugs or treatments. Diagnosis of ME/CFS is challenging due to many changing and persistent symptoms and often relies on a diagnosis of exclusion. Rheumatologists are among the handful of clinicians who treat patients with ME/CFS.

The National Institutes of Health (NIH) identified 119 Common Data Elements (CDEs) for use in people with ME/CFS. However, most CDEs are not targeted specifically for those with ME/CFS. The World Health Organization (WHO) International Classification of Functioning, Disability and Health (ICF) provides a framework to understand CDE items. The aim of this study is to use the ICF to categorize ME/CFS CDE items administered as Patient Reported Outcome Measures (PROMs). This work will provide a foundation to select the most appropriate CDE assessments and guide future development of an advanced, psychometrically-sound symptom based Computerized Adaptive Test (CAT) to assist rheumatology professionals in the treatment of patients with ME/CFS.

Methods: We reviewed all CDEs and excluded those that: 1) are not PROMs; 2) provide participant socio-demographic characteristics and medical history only; 3) use visual or pictographic scales; or 4) are for pediatric patients only.

We applied ICF linking rules1 to identify and code meaningful concepts for all items. Items were divided among five researchers for independent coding and codes were compared. Coding discrepancies were noted and discussed until a consensus was achieved (Table 1. ICF Coding Example).

Results: We identified 36 PROMs comprised of 944 items (Figure 1). All coded items fit into two ICF components: (1) Body Function (b codes) and (2) Activity and Participation (d codes). Body Function codes were as follows: Energy and drive (most frequently used), 14.9% (n=210) of the 1413 total codes; Sensation of pain 14.7% (n=208); Sleep functions 11.9% (n=168); Fatiguability 11.5% (n=163); and Emotional functions 9.7% (n=137). Only 11.1% (n=157) of items were coded in the Activity and Participation component. Table 2 presents ICF codes for core ME/CFS symptoms and functions.

Conclusion: NIH ME/CFS CDEs are comprised of items that assess key areas of Body function; however, relatively few items assess the impact of ME/CFS symptoms on Activity and Participation. Extreme limitation in the ability to engage in physical and cognitive activities is a hallmark of ME/CFS. Results demonstrate the value of using the ICF conceptual framework to examine item content to assist rheumatology professionals in selecting appropriate assessments for their patients and to inform the future development of item banks for psychometrically-sound assessments.

1.Cieza A, et al. (2005). J Rehabil Med.


Disclosures: H. Bailey, None; A. Vasudevan, None; E. Hickey, None; A. Ledingham, None; M. Slavin, None; L. Kazis, MediWound, 2; R. Tompkins, None.

To cite this abstract in AMA style:

Bailey H, Vasudevan A, Hickey E, Ledingham A, Slavin M, Kazis L, Tompkins R. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Creating a Foundation for Linking Patient Reported Outcomes Measures with the International Classification of Functioning, Disability and Health [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/myalgic-encephalomyelitis-chronic-fatigue-syndrome-creating-a-foundation-for-linking-patient-reported-outcomes-measures-with-the-international-classification-of-functioning-disability-and-health/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myalgic-encephalomyelitis-chronic-fatigue-syndrome-creating-a-foundation-for-linking-patient-reported-outcomes-measures-with-the-international-classification-of-functioning-disability-and-health/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology